Predicting chemosensitivity in osteosarcoma prior tochemotherapy: An investigational study of biomarkers with immunohistochemistry

Oncology Letters

Volumn 3, Issue 5, 2012, Pages 1011-1016

  Chen, Yong ^a,b   Yang, Yun ^c   Yuan, Zhanna ^d   Wang, Chunmeng ^a,b   Shi, Yingqiang ^a,b  

^a FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^b FUDAN UNIVERSITY   (China)

^c TIANJIN MEDICAL UNIVERSITY   (China)

^d Key Laboratory of Cancer Prevention and Treatment   (China)

Author keywords

Apurinic endonuclease 1; Cycloogenase 2; Hypoxia inducible factor 1 ; Osteosarcoma; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; CYCLOOXYGENASE 2; DEOXYRIBONUCLEASE I; DOXORUBICIN; EOSIN; HEMATOXYLIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IFOSFAMIDE; METHOTREXATE; VASCULOTROPIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CHEMOSENSITIVITY; CHILD; CLINICAL ARTICLE; DISEASE FREE SURVIVAL; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; OSTEOSARCOMA; PROGNOSIS; PROTEIN EXPRESSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TISSUE SECTION; TUMOR NECROSIS;

EID: 84863278104     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.604     Document Type: Article

References (25)

1. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC and Gebhardt MC: Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 429: 286-291, 2004.
2. Bramwell VHC: The role of chemotherapy in osteogenic sarcoma. Crit Rev Oncol Hematol 20: 61-85, 1995.
3. Bramwell VHC: The role of chemotherapy in the management of non-metastatic operable extremity osteosarcoma. Semin Oncol 24: 561-571, 1997.
4. Liu L, Ning X, Sun L, Zhang H, Shi Y, Guo C, et al: Hypoxia-inducible factor-1 alpha contributes to hypoxia-induced chemoresistance in gastric cancer. Cancer Sci 99: 121-128, 2008.
5. Quintero M, Mackenzie N and Brennan PA: Hypoxia-inducible factor 1 (HIF-1α) in cancer. Eur J Surg Oncol 30: 465-468, 2004.
6. Russell DL, Ian S and Adrian L: The role of hypoxia-inducible factor-1 in three dimensional tumor growth, apoptosis and regulation by the insulin-signaling pathway. Cancer Res 65: 4147-4152, 2005.
7. Yang QC, Zeng BF, Dong Y, Shi ZM, Jiang ZM and Huang J: Overexpression of hypoxia-inducible factor-1a in human osteosarcoma: correlation with clinicopathological parameters and survival outcome. Jpn J Clin Oncol 37: 127-134, 2007.
8. Mizobuchi H, Castellano JMG, Philip S, Healey JH and Gorlick R: Hypoxia markers in human osteosarcoma: an exploratory study. Clin Orthop Relat Res 466: 2052-2059, 2008.
9. Wu Q, Yang SH, Ye SN and Wang RY: Therapeutic effects of RNA interference targeting HIF-1 alpha gene on human osteosarcoma. Nail Med J Chin 85: 409-413, 2005.
10. Cai W, Chen A, Guo F and Zhu B: Effects of HIF-1α antisense oligonucleotides on the expression of HIF-1α and VEGF in the osteosarcoma cell line MG-63. Chi J Clin Oncol 33: 1-5, 2006.
11. Ho QT and Kuo CJ: Vascular endothelial growth factor: biology and therapeutic applications. Int J Biochem Cell Biol 39: 1349-1357, 2007.
12. Sak SC, Harnden P, Johnston CF, Paul AB and Kiltie AE: APE1 and XRCC1 protein expression levels predict cancer-specific survival following radical radiotherapy in bladder cancer. Clin Cancer Res 11: 6205-6211, 2005.
13. Yang JL, Yang D, Cogdell D, Du XL, Li HX, Pang Y, et al: APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis and survival. Technol Cancer Res Treat 9: 161-169, 2010.
14. Geng YH, Wan CX and Chen PH: Expressions of Cox-2 and HIF-lα and their relationship with clinicopathologic characteristics of osteosarcoma. Tumor 28: 427-430, 2008.
15. Dickens S and Cripe TP: Effect of combined cyclooxygenase-2 and matrix metalloproteinase inhibition on human sarcoma xenografts. J Pediatr Hematol Oncol 25: 709-714, 2003.
16. Subbaramaiah K and Dannenberg AJ: Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol Sci 24: 96-102, 2003.
17. American Joint Committee on Cancer: AJCC Cancer Staging Manual. Greene FL, Balch CM, Page DL, Haller DG, Fleming ID, Morrow M and Fritz AG (eds). 6th edition. Springer-Verlag, New York, 2002.
18. Ferrari S and Palmerini E: Adjuvant and neoadjuvant combination chemotherapy for osteogenic sarcoma. Curr Opin Oncol 19: 341-346, 2007.
19. Rosen G, Caparros B, Huvos AG, et al: Preoperative chemotherapy for osteogenic sarcoma: selection of post-operative adjuvant chemotherapy based on the response of the primary tumor to preoperative chemotherapy. Cancer 49: 1221-1230, 1982.
20. Kaya M, Wada T, Akatsuka T, et al: Vascular endothelial growth factor expression in untreated osteosarcoma is predictive of pulmonary metastasis and poor prognosis. Clin Cancer Res 6: 572-577, 2000.
21. Wu Q, Yang SH, Wang RY, Ye SN, Xia T and Ma DZ: Effect of silencing HIF-1α by RNA interference on expression of vascular endothelial growth factor in osteosarcoma cell line SaOS-2 under hypoxia. Chin J Cancer 24: 531-535, 2005.
22. Bielack SS, Kempf-Bielack B, Delling G, et al: Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 20: 776-790, 2002.
23. Lee JA, Jung JS, Kim DH, et al: RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer 56: 738-743, 2011.
24. Li Y, Dang TA, Shen J, Hicks J, Chintagumpala M, Lau CC, et al: Plasma proteome predicts chemotherapy response in osteosarcoma patients. Oncol Rep 25: 303-314, 2011.
25. Gougelet A, Pissaloux D, Besse A, Perez J, Duc A, Dutour A, et al: Micro-RNA profiles in osteosarcoma as a predictive tool for ifosfamide response. Int J Cancer 129: 680-690, 2011.